OR

349.7

-0.43%↓

B.US

40.78

+6.34%↑

ASM

638.8

+1.75%↑

IAG.ES

4.02

-0.25%↓

SY1

73.18

-1.48%↓

OR

349.7

-0.43%↓

B.US

40.78

+6.34%↑

ASM

638.8

+1.75%↑

IAG.ES

4.02

-0.25%↓

SY1

73.18

-1.48%↓

OR

349.7

-0.43%↓

B.US

40.78

+6.34%↑

ASM

638.8

+1.75%↑

IAG.ES

4.02

-0.25%↓

SY1

73.18

-1.48%↓

OR

349.7

-0.43%↓

B.US

40.78

+6.34%↑

ASM

638.8

+1.75%↑

IAG.ES

4.02

-0.25%↓

SY1

73.18

-1.48%↓

OR

349.7

-0.43%↓

B.US

40.78

+6.34%↑

ASM

638.8

+1.75%↑

IAG.ES

4.02

-0.25%↓

SY1

73.18

-1.48%↓

Search

UPM-Kymmene Oyj

Suletud

26.74 1.94

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.23

Max

26.95

Põhinäitajad

By Trading Economics

Sissetulek

241M

257M

Müük

14M

2.3B

P/E

Sektori keskmine

28.791

32.671

Aktsiakasum

0.57

Dividenditootlus

5.79

Kasumimarginaal

11.116

Töötajad

14,624

EBITDA

435M

614M

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

5.79%

3.04%

Järgmine tulemuste avaldamine

29. apr 2026

Turustatistika

By TradingEconomics

Turukapital

1.4B

14B

Eelmine avamishind

24.8

Eelmine sulgemishind

26.74

UPM-Kymmene Oyj Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. märts 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Nike, RH, NCino

31. märts 2026, 22:35 UTC

Tulu

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1. apr 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31. märts 2026, 23:50 UTC

Omandamised, ülevõtmised, äriostud

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31. märts 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31. märts 2026, 23:33 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31. märts 2026, 23:21 UTC

Tulu

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31. märts 2026, 23:14 UTC

Market Talk
Tulu

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31. märts 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss Widens >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31. märts 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31. märts 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31. märts 2026, 21:35 UTC

Tulu

Nike Expects China Sales Down 20% in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31. märts 2026, 21:33 UTC

Tulu

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31. märts 2026, 21:32 UTC

Tulu

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31. märts 2026, 21:28 UTC

Tulu

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31. märts 2026, 21:26 UTC

Tulu

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31. märts 2026, 21:25 UTC

Tulu

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31. märts 2026, 21:24 UTC

Market Talk
Tulu

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31. märts 2026, 21:22 UTC

Tulu

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31. märts 2026, 21:22 UTC

Tulu

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31. märts 2026, 21:21 UTC

Tulu

Nike's Digital Channel Still Too Promotional, CFO Says

31. märts 2026, 21:20 UTC

Tulu

Nike CEO: Converse Remains Important to Portfolio

Võrdlus sarnastega

Hinnamuutus

UPM-Kymmene Oyj Prognoos

Finantsandmed

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest UPM-Kymmene Oyj

UPM-Kymmene Oyj, together with its subsidiaries, engages in the forest-based bioindustry in Europe, North America, Asia, and internationally. It operates through UPM Fibres, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers, UPM Plywood, and Other Operations segments. The company provides softwood, birch, and eucalyptus pulp for tissue, specialty, and graphic papers and packaging; sawn timber for joinery, packaging, furniture, planning, and construction industries; and wood-based renewable diesel and renewable naphtha for transport and petrochemical industry. It is also involved in the generation of electricity through hydro, thermal, and nuclear power plants. In addition, the company offers self-adhesive label materials for branding and promotion, information, and functional labeling in the food, beverage, personal care, pharmaceutical, and logistics segments; and specialty packaging materials, such as label papers, release liners, office papers, and flexible packaging for labeling, packing, commercial siliconizing, and printing, as well as graphic papers for advertising, publishing, and home and office use. Further, it provides plywood and veneer products for construction, vehicle flooring, liquefied natural gas shipbuilding, and parquet manufacturing, as well as for other industrial applications; wood and wood-based biomass, and forestry services for forest investors and owners; wood-based biomedical products, such as nano-fibrillar cellulose for clinical and life science applications; wood-based lignin products for industrial use; and UPM ProFi decking products and UPM formi granules. Additionally, the company offers financial portfolio management services. UPM-Kymmene Oyj was founded in 1871 and is headquartered in Helsinki, Finland.
help-icon Live chat